Nelson Kathryn M, Bisson Jonathan, Singh Gurpreet, Graham James G, Chen Shao-Nong, Friesen J Brent, Dahlin Jayme L, Niemitz Matthias, Walters Michael A, Pauli Guido F
Department of Medicinal Chemistry, Institute for Therapeutics Discovery and Development, University of Minnesota, Minneapolis, Minnesota 55414, United States.
Center for Natural Product Technologies, Program for Collaborative Research in the Pharmaceutical Sciences (PCRPS), and Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, Chicago, Illinois 60612, United States.
J Med Chem. 2020 Nov 12;63(21):12137-12155. doi: 10.1021/acs.jmedchem.0c00724. Epub 2020 Sep 10.
This Perspective of the published essential medicinal chemistry of cannabidiol (CBD) provides evidence that the popularization of CBD-fortified or CBD-labeled health products and CBD-associated health claims lacks a rigorous scientific foundation. CBD's reputation as a cure-all puts it in the same class as other "natural" panaceas, where valid ethnobotanicals are reduced to single, purportedly active ingredients. Such reductionist approaches oversimplify useful, chemically complex mixtures in an attempt to rationalize the commercial utility of natural compounds and exploit the "natural" label. Literature evidence associates CBD with certain semiubiquitous, broadly screened, primarily plant-based substances of undocumented purity that interfere with bioassays and have a low likelihood of becoming therapeutic agents. Widespread health challenges and pandemic crises such as SARS-CoV-2 create circumstances under which scientists must be particularly vigilant about healing claims that lack solid foundational data. Herein, we offer a critical review of the published medicinal chemistry properties of CBD, as well as precise definitions of CBD-containing substances and products, distilled to reveal the essential factors that impact its development as a therapeutic agent.
这篇已发表的关于大麻二酚（CBD）基础药物化学的观点文章表明，CBD强化或贴有CBD标签的健康产品的普及以及与CBD相关的健康声明缺乏严格的科学依据。CBD作为万灵药的声誉使其与其他“天然”万灵药归为一类，在这些万灵药中，有效的民族植物药被简化为单一的、据称具有活性的成分。这种还原论方法过度简化了有用的、化学结构复杂的混合物，试图使天然化合物的商业用途合理化，并利用“天然”标签。文献证据表明，CBD与某些半普遍存在、经过广泛筛选、主要基于植物的物质相关，这些物质纯度未明，会干扰生物测定，且成为治疗剂的可能性较低。广泛存在的健康挑战和大流行危机，如SARS-CoV-2，创造了这样的环境，即科学家必须对缺乏坚实基础数据的治疗声称格外警惕。在此，我们对已发表的CBD药物化学性质进行批判性综述，并对含CBD的物质和产品给出精确定义，以揭示影响其作为治疗剂发展的关键因素。
